Can telehealth boost HIV prevention in underserved communities?

NCT ID NCT05528653

Completed Prevention Sponsor: Vivent Health Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether offering HIV PrEP (a daily pill that prevents HIV) through telehealth visits could help more Black and Latino men who have sex with men start and stay on the medication. Researchers enrolled 75 HIV-negative men and provided PrEP care remotely. The goal was to see if removing the need to visit a clinic in person would increase uptake and continuation of PrEP in these communities.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Descovy (HIV PrEP drug)
What this could lead to: If successful, this approach could make HIV prevention more accessible for Black and Latino men who have sex with men, reducing new infections.
What could go wrong: This is a small, completed Phase 4 study (75 participants) without a control group, so results may not apply broadly. Telehealth may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PREVENTION

Contacts and locations

Locations

Vivent Health

Denver, Colorado, 80245, United States
Vivent Health

St Louis, Missouri, 63103, United States
Viventh Health

Milwaukee, Wisconsin, 53203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.